Terbinafine, a diminutive molecule that bears immense pharmacological prowess, exhibits its inhibitory functions via the obstruction of SQLE - a pivotal enzyme in the biosynthesis of ergosterol, the cardinal component of fungal cell membranes. As a result of this inhibition, terbinafine assails the fungal cell membrane, prompting a cascade of events that ultimately culminate in the fungus's untimely demise. Terbinafine has been employed in the clinical realm to treat an array of fungal infections, including onychomycosis and tinea cruris. This drug was granted the stamp of approval by the FDA in April of 1998 and was developed by GSK. Click on the image below to begin the exploration journey of Terbinafine through the Synapse database!
You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!